The short version of GRF(1-29) fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-02. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
The Director General functions from the West Bengal Police Directorate, located in the Writers' Buildings, the State Government's main Secretariat in Central Kolkata. He is assisted by a team of senior officers from the ranks of Additional Director General & Inspector General of Police to Assistant Inspector General of Police (AIG — a post equivalent in rank and status to the Superintendent of Police). Officers of the rank of Deputy Superintendent of Police are selected by the West Bengal Public Service Commission through the West Bengal Civil Service (Executive & other services) examinations. In addition to this, the directly recruited Sub Inspectors of Police may also become Deputy Superintendent of Police on promotion. The West Bengal Police maintains the following ranks:
RCH=CH2 + H2 + CO → RCH2−CH2CHO Rh-based hydroformylation underpins the industrial production of products as diverse as detergents, fragrances, and some drugs. Rhodium based catalysts have 1000 to 10000 times higher activity for hydroformylation than cheaper cobalt carbonyl-based catalysts, allowing reactions at lower temperatures and pressures. Rhodium is also known to catalyze many reactions involving hydrogen gas and hydrosilanes. These include hydrogenations and hydrosilylations of alkenes. Rhodium metal, but not rhodium complexes, catalyzes the hydrogenation of benzene to cyclohexane.
==== Desiccation stress ==== Desiccation (drought) stress is defined as conditions where water becomes the growth limiting factor. MAAs have been reportedly found in high concentrations in many microorganisms exposed to drought stress. Particularly cyanobacteria species that are exposed to desiccation, UV radiation and oxidation stress have been shown to possess MAA's in an extracellular matrix. However it has been shown that MAAs do not provide sufficient protection against high doses of UV radiation.
== Incomplete list of secreted proteins == α-Amylase (1A, 1B, 1C) – begins break down of carbohydrates, especially starch. Antileukoproteinase (SLPI) – antimicrobial protein that acts as a protease inhibitor. It is also found in mucous membranes located in other parts of the body. Carbonic anhydrase 6 (CA6) – enzyme that can convert carbonic acid into water and CO2, which may function to regulate saliva pH. Histatin (HTN1, HTN3) – have a variety of roles from inhibiting fungus growth, acting as precursors for enamel, and promoting wound healing. Lactoperoxidase – reacts with thiocyanate ions to produce antimicrobial molecules. Lactoferrin – antimicrobial protein that binds to iron, and is also found in high concentrations in milk. Proline rich proteins – inhibit calcium phosphate crystal formation and provide a suitable environment for enamel protection and repair. Basic (1, 2, 3, 4) Acidic (1, 2) Proline-rich protein 4 (PRR4) – also produced by lacrimal acinar cells Statherin – helps stabilize saliva and prevent calcium precipitation.
Sources: en.wikipedia.org
Extensive study has been performed on compounds of the form M4AnO2(CO3)3, where M represents a monovalent cation and An is either uranium, neptunium, or plutonium. Since 1967, when neptunium(VII) was discovered, some coordination compounds with neptunium in the +7 oxidation state have been prepared and studied. The first reported such compound was initially characterized as Co(NH3)6NpO5·nH2O in 1968, but was suggested in 1973 to actually have the formula [Co(NH3)6][NpO4(OH)2]·2H2O based on the fact that Np(VII) occurs as [NpO4(OH)2]3− in aqueous solution. This compound forms dark green prismatic crystals with maximum edge length 0.15–0.4 mm.
== Research == A relatively recent avenue of drug research in treating depression and drug addiction is through PPARα and PPARγ activation. Both TLR4-mediated and NF-κB-mediated signalling pathways have been implicated in the development of addiction to several drugs such as opioids and cocaine, and therefore are appealing targets for pharmacotherapy. Despite a breadth of preclinical research showing potential in animal models in the treatment of drug addictions including alcohol, nicotine, cocaine, opioids and methamphetamine, the human evidence is limited with the amount of trials looking at using PPAR agonists for humans still being low; and so far (as of 2020) not being particularly promising. There are several suggested hypotheses for the poor translation from animal to human research evidence such as the potency and selectivity of PPAR ligands, sex-related variability, and species differences in the distribution and signaling of PPAR.
In 2010, Latynina criticised the Tagliavini report, saying: "A war, it turns out, is begun by he [sic] who responds to the actions of an aggressor [...]. So when Ossetian 'volunteers' burn Georgian villages - that is not a war. But if they [the Georgians] respond to this, then here you, accursed ones, have started a war." Latynina argued that according to the Tagliavini mission "Georgia had no right to send a single shell into the city [of Tskhinvali]. But the opposite side had a right to burn down Nuli, and that was not an infringement of human rights." Latynina concluded that the commission showed a "cowardice" before "an international hooligan" Vladimir Putin. Latynina called the report "a new Munich Agreement" and stated that "The prevailing motive in the report was to avoid at all costs spoiling relations with Russia". Latynina again criticised Tagliavini for the report during the events in Crimea in 2014, and again in 2015.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.